Tau-containing vesicles display aberrant sialylation patterns that can be targeted by engineered lectins or glycan-binding antibodies to selectively capture and neutralize pathological tau before aggregation. These 'molecular nets' would exploit unique glycan signatures as biomarkers for therapeutic intervention.
Auto-built from this analysis's top knowledge-graph edges.
graph TD
ST6GAL1["ST6GAL1"] -->|regulates| sialylation["sialylation"]
ST6GAL1_1["ST6GAL1"] -->|catalyzes| sialylation_2["sialylation"]
ST6GAL1_3["ST6GAL1"] -->|associated with| tau_spreading["tau_spreading"]
style ST6GAL1 fill:#ce93d8,stroke:#333,color:#000
style sialylation fill:#ffd54f,stroke:#333,color:#000
style ST6GAL1_1 fill:#ce93d8,stroke:#333,color:#000
style sialylation_2 fill:#4fc3f7,stroke:#333,color:#000
style ST6GAL1_3 fill:#ce93d8,stroke:#333,color:#000
style tau_spreading fill:#4fc3f7,stroke:#333,color:#000No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for ST6GAL1 yet. Search RCSB →
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for ST6GAL1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF we administer ST6GAL1-targeted engineered galectin-3-Fc fusion proteins (10 mg/kg, twice weekly, i.p.) to P301S tau transgenic mice at 3 months of age for 12 weeks, THEN we will observe a statistic | ≥40% reduction in Sarkowski-positive tau aggregates in hippocampus and entorhinal cortex; decreased insoluble tau fraction by ≥50% on Western blot; improved per | — no observation — | pending | 0.35 |
| IF we perform sialic acid-specific lectin microarray analysis on plasma-derived extracellular vesicles from 200 early-stage Alzheimer's disease patients ( CDR 0.5-1 ) versus 200 age-matched cognitivel | ≥2-fold increase in α2,6-sialylated glycan signal (SNA-I lectin binding) on CD81+/Tau+ extracellular vesicles in AD patients; ROC AUC ≥0.75 for discriminating A | — no observation — | pending | 0.28 |